Grace Therapeutics is a clinical-stage biopharmaceutical company that reformulates approved compounds to treat rare and orphan diseases. The company employs proprietary drug delivery technologies to improve bioavailability and administration. Grace Therapeutics focuses primarily on its lead asset, GTx-104, an IV nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). While nimodipine is the standard treatment for aSAH, it is currently only available in oral forms that suffer from low bioavailability and administration challenges in intensive care settings. GTx-104 utilizes nanoparticle technology to enable peripheral IV delivery, which achieves 100% bioavailability at one-twelfth the oral dose. A Phase 3 trial for GTx-104 met its primary endpoint by reducing hypotension episodes versus oral nimodipine. The FDA issued a Complete Response Letter in April 2026 citing manufacturing deficiencies at a contract manufacturer. Grace Therapeutics has deferred development of its other candidates, GTx-102 and GTx-101, to prioritize GTx-104. The company plans to sell GTx-104 directly to U.S. hospitals and stroke centers using a targeted sales force. Grace Therapeutics follows an asset-light model by outsourcing all manufacturing and maintains protection through patents and Orphan Drug Exclusivity.